Propel Bio Management’s Vor Biopharma VOR Stock Holding History

Propel Bio Management’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-314,543	Closed	-$5.59M	–	37
2026 Q1	$5.59M	Buy	+314,543	New	+$4.44M	3.52%	7

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Propel Bio Management's VOR Position: Q2 2026 in Review

Propel Bio Management sold out of Vor Biopharma (VOR) in Q2 2026, closing a stake of 314,543 shares — an estimated $5.59M sold.

Propel Bio Management first reported a position in VOR in Q1 2026 and held it in 1 quarter. The position peaked at $5.59M in Q1 2026. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

Propel Bio Management reported no remaining Vor Biopharma position as of Q2 2026 after selling out during the quarter.
Propel Bio Management sold 314,543 Vor Biopharma shares in Q2 2026, an estimated $5.59M.
Propel Bio Management first reported a position in Vor Biopharma in Q1 2026 and held it in 1 quarter.
Propel Bio Management's Vor Biopharma position peaked at $5.59M in Q1 2026.
102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.